CLDND1

CLDND1 (claudin domain-containing 1) is a claudin-like protein that maintains endothelial tight junction integrity and barrier function, with its expression controlled by a converging set of transcriptional and post-transcriptional inputs (PMID:33037622, PMID:42176037). Transcriptionally, CLDND1 is directly activated by MZF1, which binds a silencer element in the first intron; MZF1 loss reduces CLDND1 and increases endothelial permeability (PMID:33037622). EGFR-MAPK signaling provides a second activating input through EGF-dependent ELK1 phosphorylation, which drives CLDND1 expression via an enhancer near the promoter and is blocked by the EGFR inhibitor gefitinib (PMID:35892692). Post-transcriptionally, miR-124/miR-124-3p represses CLDND1 by binding a conserved 3'-UTR site, and loss of CLDND1 in cerebral ischemia-reperfusion models drives endothelial-mesenchymal transition with downregulated occludin and upregulated α-SMA and Snail, while restoring CLDND1 rescues endothelial function (PMID:29530526, PMID:42176037). In cancer cells, CLDND1 functions as a survival factor: its knockdown induces caspase-3-dependent intrinsic apoptosis with cytochrome C release, partly buffered by compensatory ERK1/2 activation whose pharmacological blockade potentiates cell death (PMID:26083392). An upstream miR-199a-3p–FTO–m6A axis modulates MZF1 and thereby CLDND1 levels in NSCLC cells (PMID:41201047).

1. 2015 Medium

   Established that CLDND1 is not merely a structural junction protein but a survival factor in cancer cells, defining the apoptotic consequence of its loss and a compensatory ERK1/2 escape mechanism.

   Evidence siRNA knockdown with apoptosis markers (caspase-3/PARP cleavage, cytochrome C release) and MEK1/2 inhibitor epistasis in basal-like breast cancer lines

   PMID:26083392

   Open questions at the time

   • Molecular mechanism linking CLDND1 loss to mitochondrial apoptosis not defined
   • How CLDND1 depletion augments ERK1/2 phosphorylation unknown
   • Single-lab observation in breast cancer lines only
2. 2018 Medium

   Identified the first post-transcriptional regulator of CLDND1, showing miR-124 directly represses it via a 3'-UTR site, linking CLDND1 dosage to endothelial/vascular contexts.

   Evidence Luciferase reporter with sequence-specific 3'-UTR mutations, miR-124 mimic in brain endothelial cells, and in vivo SHRSP correlation

   PMID:29530526

   Open questions at the time

   • Functional barrier consequence of the miR-124–CLDND1 axis not tested here
   • Correlative in vivo data do not prove causation in SHRSP
3. 2020 High

   Defined the first direct transcriptional activator of CLDND1 and tied its regulation to a measurable barrier function readout.

   Evidence ChIP and luciferase reporter mapping MZF1 to an intronic silencer element, with MZF1 knockdown increasing FITC-dextran permeability in brain endothelial cells

   PMID:33037622

   Open questions at the time

   • Whether MZF1 cooperates with other factors at the locus unknown
   • Mechanism by which CLDND1 maintains barrier tightness not addressed
4. 2022 High

   Connected CLDND1 transcription to upstream growth-factor signaling, showing EGFR-MAPK acts through ELK1 to induce expression.

   Evidence ChIP and luciferase reporter for ELK1 at an enhancer, EGF stimulation, and gefitinib inhibition with RT-qPCR/western readouts

   PMID:35892692

   Open questions at the time

   • Cell-type breadth of EGF-ELK1-CLDND1 induction not established
   • Functional outcome of EGF-driven CLDND1 induction not tested
5. 2025 Medium

   Extended MZF1 control of CLDND1 to NSCLC and placed an epitranscriptomic miR-199a-3p–FTO–m6A axis upstream of MZF1.

   Evidence Dual-luciferase, MeRIP, PAR-CLIP, siRNA/overexpression in A549 cells

   PMID:41201047

   Open questions at the time

   • Direct effect of CLDND1 on malignant behavior not isolated from upstream axis
   • Single cell line and single lab
6. 2026 Medium

   Demonstrated a functional consequence of CLDND1 loss in vascular disease, showing it suppresses endothelial-mesenchymal transition and that restoring it rescues barrier markers.

   Evidence Dual-luciferase, OGD/R and MCAO/R models, circ_0017866 sponging of miR-124-3p, with occludin/α-SMA/Snail readouts in vitro and in vivo

   PMID:42176037

   Open questions at the time

   • Direct molecular role of CLDND1 in suppressing EndMT not mechanistically resolved
   • Single-lab ischemia-reperfusion models

• The biochemical mechanism by which CLDND1 itself maintains tight junctions and suppresses apoptosis—its junctional partners, structure, and direct molecular activity—remains uncharacterized.
• No direct physical interaction partners identified
• No structural or domain-level mechanism for barrier function
• Mechanistic link between CLDND1 and intrinsic apoptosis machinery unresolved